The patients receiving dual-ICB therapy had a better response than those who administrated mono-immunotherapy with a tendency toward statistical significance (p=0.074) ( figure 3B ).
← all excerpts
Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
2
0.0740
0.0740
The sentences
There were nearly significant differences in tumor mutational burden (TMB) level and SMARCA4 mutation frequency between the ICB response and non-response group.